Obesity Market Positioned For Accelerated Development Through 2034, Delveinsight Finds Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, Proqr Therapeutics, Nano Precision Medical, Bukwang Pharma

(MENAFN- GetNews)

The Key Obesity Companies in the market include - Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others.

DelveInsight's “Obesity Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Obesity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obesity Market Forecast

Some of the key facts of the Obesity Market Report:

• The Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In July 2025, Hengrui Pharma , in collaboration with Kailera Therapeutics, announced positive topline results from its Phase III trial (HRS9531-301) evaluating weekly subcutaneous injections of HRS9531 in adults with obesity or overweight in China. The study included participants with at least one weight-related comorbidity, excluding those with diabetes. A total of 567 individuals were enrolled and randomly assigned to receive HRS9531 at doses of 2 mg, 4 mg, 6 mg, or a placebo over 48 weeks. Of these, 531 participants successfully completed the trial.

• In June 2025, Novo Nordisk is advancing both injectable and oral formulations of amycretin into Phase III clinical trials for individuals with obesity or overweight. After a favorable end-of-Phase II meeting, the company confirmed that regulatory authorities have granted clearance to move forward. The Phase III trial is expected to begin in the first quarter of 2026, targeting adults with overweight or obesity.

• In June 2025, Arrowhead Pharmaceuticals administered the first dose in the Phase I/IIa AROALK7-1001 trial of ARO-ALK7, an investigational RNA interference (RNAi) therapy targeting obesity. The study will initially enroll healthy obese participants to receive single and multiple escalating doses of ARO-ALK7 as a standalone treatment. The trial is planned to quickly progress to evaluate the therapy in combination with tirzepatide in obese individuals, both with and without type 2 diabetes (T2D).

• In May 2025, ICON plc (NASDAQ: ICLR), a global leader in clinical research driven by healthcare intelligence, has published the results of a survey involving 155 biotech and pharmaceutical professionals from the US and Europe. The survey focused on multi-indication cardiometabolic research and development (R&D) for therapies targeting obesity and its related conditions. Multi-indication studies refer to clinical trials that evaluate the effectiveness of a treatment across multiple diseases or conditions.

• In April 2025, Corxel Pharmaceuticals has obtained clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application, allowing the initiation of a randomized Phase II trial in the US for CX11, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) aimed at treating obesity. This double-blind, placebo-controlled study will evaluate the safety and effectiveness of the once-daily therapy in individuals who are overweight or obese. Corxel plans to begin enrolling participants in the second quarter of this year, with topline results anticipated in the first half of 2026.

• In March 2025, Zealand Pharma completed enrollment for its global, randomized Phase IIb ZUPREME-1 trial, which is evaluating petrelintide, a long-acting amylin analogue, in people with obesity or overweight and associated comorbidities. This placebo-controlled, multi-center, parallel-group study aims to compare the once-weekly subcutaneous injection of petrelintide to a placebo in terms of safety, tolerability, and impact on body weight.

• In Janaury 2025, Novo Nordisk's high-dose formulation of Wegovy (semaglutide) has demonstrated enhanced weight loss benefits while maintaining a favorable safety and tolerability profile. In the Phase IIIb STEP UP trial, the 7.2mg dose of Wegovy showed statistically significant and superior weight reduction at week 72. The study involved 1,407 adults with obesity who were randomized to receive once-weekly injections alongside lifestyle modification support.

• In January 2025, Viking Therapeutics has initiated a Phase II clinical trial for VK2735, an oral tablet developed to address metabolic conditions like obesity. The VENTURE-Oral Dosing Trial is a randomized, double-blind, placebo-controlled, multi-center study designed to evaluate the safety, tolerability, and effectiveness of the drug in promoting weight loss over a 13-week period.

• In July 2024, Roche announced promising topline results from its ongoing multi-part Phase I clinical trial of CT-996, an oral GLP-1 receptor agonist intended for the treatment of type 2 diabetes (T2D) and obesity. Known as the CT-996-201 trial, this comprehensive, multi-cohort, double-blind, randomized, placebo-controlled study includes both single and multiple ascending dose arms, with two arms already completed. The trial aims to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of CT-996 in overweight or obese adults, regardless of their T2D status.

• In 2023, the United States held the largest market share for obesity, exceeding USD 2,000 million. This surpassed the market sizes of obesity in comparison to the European Union Four (EU4) countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.

• By the year 2034, it is expected that WEGOVY (Semaglutide) and ZEPBOUND (Tirzepatide) will attain significant market dominance across the seven major markets.

• In recent times, there has been an increasing emphasis on the creation of innovative treatments for obesity, which encompass drug combinations like SAXENDA (Liraglutide), XENICAL (Orlistat), WEGOVY (Semaglutide), QYSMIA (Phentermine-Topiramate), among others .

• DelveInsight's estimates suggest that approximately 60% of the total prevalent cases of obesity among adults in the 7 major markets (7MM) were accounted for by the United States in 2023.

• Key Obesity Companies: Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others

• Key Obesity Therapies: IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others

• The Obesity market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obesity pipeline products will significantly revolutionize the Obesity market dynamics.

Obesity Overview

Obesity is a medical condition characterized by excessive body fat accumulation, which can negatively impact health. It is typically measured using the Body Mass Index (BMI), with a BMI of 30 or higher indicating obesity. This condition increases the risk of various health issues, including heart disease, diabetes, hypertension, and certain cancers. Obesity can result from multiple factors, such as poor diet, lack of physical activity, genetics, and hormonal imbalances. Effective management includes lifestyle changes, medical treatments, and, in some cases, surgical interventions to improve overall health and reduce associated risks.

Get a Free sample for the Obesity Market Forecast, Size & Share Analysis Report:

Obesity Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Obesity Epidemiology Segmentation:

The Obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Obesity

• Prevalent Cases of Obesity by severity

• Gender-specific Prevalence of Obesity

• Diagnosed Cases of Episodic and Chronic Obesity

Download the report to understand which factors are driving Obesity epidemiology trends @ Obesity Epidemiology Forecast

Obesity Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obesity market or expected to get launched during the study period. The analysis covers Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Obesity Therapies and Key Companies

• IMCIVREE (setmelanotide): Rhythm Pharmaceuticals

• ZEPBOUND (tirzepatide): Eli Lilly and Company

• Survodutide (BI 456906): Boehringer Ingelhium

• DD03: D&D Pharmatech

• AX-0601: ProQR Therapeutics

• NPM 139: Nano Precision Medical

• BK-1701: Bukwang Pharmaceutical

• CBW-520: Caliway Biopharmaceutics

• YH34160: Yuhan

• TERN-601: Terns Pharmaceuticals

• Thermostem: BioRestorative Therapies

• SCO-267: SCOHIA PHARMA

• CT-181: Click Therapeutics

• HM15136: Hanmi Pharmaceuticals

• NNC0480-0389: Novo Nordisk

• EMP-16: Empros Pharma

• CT-868: Carmot Therapeutics

• Tirzepatide: Eli Lilly and Company

• Semaglutide Oral: Novo Nordisk

Discover more about therapies set to grab major Obesity market share @ Obesity Treatment Landscape

Obesity Market Drivers

• Rise in prevalence of Obesity, growing Research and Development Activities to develop novel therapies to treat obesity, changing lifestyle patterns are some of the important factors that are fueling the Obesity Market.

Obesity Market Barriers

• However, challenges associated with the discovery of anti-obesity drugs, economic burden associated with obesity and other factors are creating obstacles in the Obesity Market growth.

Scope of the Obesity Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Obesity Companies: Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others

• Key Obesity Therapies: IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others

• Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies

• Obesity Market Dynamics: Obesity market drivers and Obesity market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

• Obesity Unmet Needs, KOL's views, Analyst's views, Obesity Market Access and Reimbursement

To know more about Obesity companies working in the treatment market, visit @ Obesity Clinical Trials and Therapeutic Assessment

Table of Contents

1. Obesity Market Report Introduction

2. Executive Summary for Obesity

3. SWOT analysis of Obesity

4. Obesity Patient Share (%) Overview at a Glance

5. Obesity Market Overview at a Glance

6. Obesity Disease Background and Overview

7. Obesity Epidemiology and Patient Population

8. Country-Specific Patient Population of Obesity

9. Obesity Current Treatment and Medical Practices

10. Obesity Unmet Needs

11. Obesity Emerging Therapies

12. Obesity Market Outlook

13. Country-Wise Obesity Market Analysis (2020–2034)

14. Obesity Market Access and Reimbursement of Therapies

15. Obesity Market Drivers

16. Obesity Market Barriers

17. Obesity Appendix

18. Obesity Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

MENAFN08092025003238003268ID1110031698